Merck & Co. Inc. (NYSE:MRK) To Present MK-7243 Phase III Study Findings
On Saturday, November 9, 2013, Merck & Co., Inc. (NYSE:MRK) announced the data for its investigational MK-7243 tablet from a Phase III clinical study involving 1,501 North American adult and pediatric patients. MK-7243 is a Timothy grass sublingual allergy immunotherapy tablet that had been accepted by the U.S. Food and Drug Administration for review Biologics License Applications alongside that of ragweed pollen sublingual allergy immunotherapy tablet. The company anticipates these reviews by the USFDA to be completed during 1H14. To develop the sublingual allergy immunotherapy tablets, Merck had partnered with ALK-Abello.
The results for MK-7243 showed that the therapy demonstrated significant improvement in TCS (Total Combined Score), DSS (Daily Symptom Score) and DMS (Daily Medication Score) compared to placebo. Dr. David Bernstein, one of the study investigators and professor of Medicine and Environmental Health at University of Cincinnati College of Medicine, said that patients in this clinical study who took the investigational MK-7243 tablet showed a promising improvement in common allergy symptoms during the entire grass season.
The Vice President of Respiratory and Immunology at Merck Research Laboratories, Dr. Sean Curtis commented that few large studies have evaluated sublingual immunotherapy for allergic rhinitis in distinctive demographic groups involving adults and children. Dr. Sean expressed that it is really a matter of proud that Merck is exploring this potential new option for Timothy grass pollen-induced allergic rhinitis therapy in North America.
The findings from this clinical study are going to be presented during Nov. 7-11 in Baltimore at the American College of Allergy, Asthma & Immunology (ACAAI)’s 70th Annual Scientific Meeting. Among other presenters at ACAAI, Viropharma Inc. (NASDAQ:VPHM) will also be presenting the data related to the quality of life in patients with HAE (Hereditary Angioedema) receiving Cinryze replacement therapy for prophylaxis. The company will also present the data relating to ACET (Angioedema Clinical Epidemiology Testing) initiative related to HAE.